TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today commentary by South Asian physician Hamayle Saeed describes a mismatch between lower BMI thresholds used to screen Asian Americans for diabetes and the higher thresholds commonly used for GLP-1 weight-loss coverage. The piece cites research and changing clinical guidance, but does not establish how often insurers deny treatment on this basis or whether coverage rules will change.
South Asian physician Hamayle Saeed says she was screened for diabetes under a lower BMI threshold used for Asian Americans but could not qualify for a GLP-1 weight-loss prescription at a BMI of 26.5 because she lacked the additional condition required under commonly applied U.S. eligibility criteria. In an October 31 MedPage Today commentary, Saeed argues the mismatch can leave Asian patients flagged as being at elevated diabetes risk while falling below thresholds used by insurers and clinicians to authorize treatment.
Saeed writes that the American Diabetes Association recommends diabetes screening for Asian Americans beginning at a BMI of 23, reflecting evidence that diabetes risk can arise at lower body weights in Asian populations. She says her doctor screened her under that approach. She also reports that she was told she did not qualify for a GLP-1 receptor agonist for weight loss: the criteria she describes generally require a BMI of 30, or a BMI of 27 with at least one weight-related condition. At 26.5 and without diabetes, she met neither threshold.
The commentary says coverage for GLP-1 drugs used for weight loss has contracted in some public programs. Saeed reports that Medi-Cal dropped coverage in January and MassHealth followed in July. Those dates and policy descriptions are reported in the commentary; the article does not provide program notices or details of exceptions, appeals, or other coverage pathways.
Saeed also cites a 2026 analysis of 352 GLP-1 trials, which she says found BMI cutoffs excluded a larger share of Asian than non-Asian American adults from trial eligibility. A separate 2025 study, STEP 11, tested semaglutide in South Korea and Thailand using a local obesity threshold of BMI 25. The reported post hoc analysis of 68 participants below BMI 30 found greater average weight loss among those receiving semaglutide than placebo. These findings concern trial participants and do not, by themselves, establish coverage eligibility or treatment outcomes for every patient.
When Screening and Coverage Diverge
The issue is a gap between risk assessment and access rules. A screening threshold is intended to identify people who may need testing; it is not automatically a prescription standard. But when clinical definitions recognize elevated risk at a lower BMI while coverage forms retain higher cutoffs, some patients may be assessed as at risk yet remain ineligible for a treatment they seek.
That distinction matters for Asian American patients because BMI does not capture body composition or health risk identically across populations. Saeed cites evidence that people of Asian descent may have more visceral fat and less muscle at a given BMI, and that diabetes can develop at lower BMI levels. The commentary argues that a single numerical coverage rule may therefore miss differences relevant to care. Whether changing that rule would improve outcomes, and how payers would balance evidence, cost and eligibility, remains a policy question rather than a conclusion established by the cited examples.
Coverage limits also have immediate practical consequences. Where public programs remove or narrow benefits, patients who are near a cutoff may have fewer routes to treatment. The commentary brings together clinical guidance, trial participation and insurance rules to show why those systems can send different signals about the same patient.
Products Worth Considering
Withings BPM Connect Smart Blood Pressure Monitor
Oura Ring 4 Smart Ring – Silver – Size 8
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
As an affiliate, we earn on qualifying purchases.
How BMI Rules Reached This Point
The World Health Organization identified lower BMI action points for Asian populations in 2004, including 23 and 27.5. Saeed cites a study of nearly 1.5 million adults in England that compared diabetes risk across ethnic groups: the reported BMI at which South Asian adults reached the risk level associated with BMI 30 in white adults was 23.9; for Chinese adults, it was 26.9. These are study findings, not universal individual thresholds.
The commentary says U.S. GLP-1 eligibility rules reflect criteria used in pivotal trials, which were built around conventional Western definitions of obesity. It also reports that the 2026 ADA Standards of Care call for confirming excess adiposity with cutoffs appropriate to ethnicity, and that the 2026 semaglutide label and tirzepatide label describe indicated patients without stating a BMI number in the indication. Saeed says payer prior-authorization forms still commonly use 30 and 27. The difference between drug labeling and a particular insurer’s requirements can depend on the plan and its policies.
For comparison, Saeed points to guidance from the U.K.’s National Institute for Health and Care Excellence. The commentary says NICE uses a BMI threshold of 35 with a comorbidity for tirzepatide, while advising a 2.5-point reduction for several ethnic groups, including South Asian and Chinese patients. The comparison illustrates that policy systems can adjust thresholds differently; it does not mean the U.K. and U.S. rules are otherwise equivalent.
“The ADA guideline that flags me for annual diabetes screening and the prior authorization form that denies me the drug are describing the same 26.5. Only one of them was written with an Asian body in mind.”
— Hamayle Saeed, MD, in her MedPage Today commentary
Coverage Rules and Patient Eligibility
The commentary does not identify the insurer or plan involved in Saeed’s reported denial, provide the full prior-authorization decision, or say whether she appealed. It is also unclear how consistently U.S. payers apply BMI cutoffs, what exceptions they allow, and how often Asian patients are denied for being below a threshold despite other risk factors.
The source presents studies and clinical guidance but does not establish that lowering GLP-1 coverage thresholds for Asian patients would be appropriate in every case. The cited trial subgroup was small, and the reported weight-loss results do not settle questions about long-term outcomes, safety, cost-effectiveness or access. The commentary also does not document whether the label language it describes has led insurers to revise their forms.
Whether Payers Revise Their Criteria
The next developments to watch are changes to insurer and public-program prior-authorization rules, along with any updated guidance from medical organizations or regulators on how obesity should be defined for treatment eligibility. The MedPage Today commentary calls attention to the mismatch, but does not announce a policy change or give a timetable for one.
Patients and clinicians may need to check the specific plan’s current requirements, including whether it recognizes ethnicity-adjusted assessments or allows an appeal. Any broader change would require payers to decide how clinical evidence, drug labeling, population-specific risk and program budgets should be reflected in coverage rules.
Key Questions
What happened in this report?
South Asian physician Hamayle Saeed wrote that she was screened for diabetes under an Asian-specific BMI threshold but did not meet the BMI criteria she encountered for GLP-1 weight-loss treatment coverage. Her account appeared in a MedPage Today commentary published October 31, 2026.
Why does the commentary cite a BMI of 23?
Saeed says the American Diabetes Association recommends diabetes screening for Asian Americans beginning at a BMI of 23 because diabetes risk can occur at lower body weights in Asian populations. A screening threshold does not itself determine drug eligibility.
What BMI criteria for GLP-1 coverage does the commentary describe?
It describes common criteria of BMI 30, or BMI 27 with at least one weight-related condition. Requirements vary by insurer and plan, and the commentary does not establish a single rule that applies to every patient.
Did the reported studies change insurance coverage?
The commentary cites research and updated clinical guidance, but it does not report that insurers changed their prior-authorization rules as a result. Whether payers will adopt different thresholds remains unclear.
Source: medpagetoday.com
